-
Immunotherapy short board, to help China's esophageal cancer diagnosis and treatment to climb a new peak.
Time of Update: 2020-10-05
Esophageal cancer, as a high-risk and high-death cancer, has made very limited progress in treatment over the past decade, and it was not until recent years that immunotherapy was approved for second-
-
Lancet oncol: Effects of preoperative radiotherapy on prognosis in patients with postmenal sarcoma.
Time of Update: 2020-10-04
study aims to assess the effects of preoperative radiotherapy combined surgery and simple surgery on the recurrence of re-occurrence prognosis in patients with abdominal sarcoma.
30 (24%) and 13 (10%) severe adverse reactions occurred in the joint group and the single surgical group, respectively.
-
NEJM: Sotorasib has a significant effect in treating late-stage solid tumors with KRAS mutations.
Time of Update: 2020-10-04
There is currently no approved treatment plan for KRAS mutant tumors, and statistics show that 13% of patients with non-small cell lung cancer (NSCLC) and 1-3% of colorectal cancer and other cancers have KRASG12C mutations.
-
Br J Cancer: New PPAR astration CB11: Potential treatment for non-small cell lung cancer.
Time of Update: 2020-10-04
previous studies have shown that PPAR gamma (peroxidase proliferative activated by the ligand) astrogen induces the death of non-small cell lung cancer (NSCLC) cells.
results show that the new PPAR astrogen CB11 may become a new type of anti-cancer drug, and has a certain contribution to the treatment of radiation resistance of non-small cell lung cancer.
-
Lancet oncol: The phase III clinical trial of the domestic drug Sofantini for advanced pancreatic neuroendocrine tumors was terminated early because of the good efficacy!
Time of Update: 2020-10-04
The patients were randomly assigned to the Sovantinib group (300 mg, oral, 1/day) or placebo group at 2:1 until the disease progressed, insulable toxicity, withdrawal from the study, adverse complications, use of other anti-tumor drugs, pregnancy, loss of visitation, or the evaluation of the suspension of the patient.
-
Nat Commun: MCL-1 may be a potential therapeutic target for lung adenocarcinoma.
Time of Update: 2020-10-04
of MRL-1 in lung cancer is intended to explore the role of survival-promoting genes in cancer cell integrity during the cloning evolution of non-small cell lung cancer (NSCLC).
researchers found high-frequency MCL-1 obtained expression in several separate NSCLC queues, both in tumor cloning and subclonals.
-
Nature: Peroxidase mediates the sensitivity of tumors to iron death.
Time of Update: 2020-10-04
, researchers recently published a paper in the journal Nature, using genome-wide CRISPR-Cas9 inhibitors, and found that oxidizing cytoserter peroxidases are key contributors to iron death sensitivity in human kidney and ovarian cancer cells.
-
Odivo's complementary treatment of patients with esophageal cancer and gastroesophageal connecting cancer significantly improved disease-free survival.
Time of Update: 2020-10-04
results showed that Odivo (Navuliyu monoantigen) showed statistically significant and clinically significant improvements in esophageal cancer and gastroesophageal connection cancer patients with new assisted synchrugal chemotherapy (CRT) and surgical removal compared to placebo.
-
Cell Death Dis:lncRNA DOCK9-AS2 promotes the development of thyroid papyrotic cancer.
Time of Update: 2020-10-04
DOCK9-AS2 is an expression level increase of DOCK9-AS2 in thyroid cancer samples shown in the database of exosome lncRNA, GEPIA and circlncRNAnet, but no studies have reported the function and regulation mechanism of DOCK9-AS2 in PTC.
-
The Chinese Expert Consensus on Antiangiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer (2020 Edition) was officially released to help improve the level of clinical treatment of late NSCLC.
Time of Update: 2020-10-04
the new edition of Consensus further affirms the indispensable position of anti-angiogenesic drugs in the treatment of advanced non-small cell lung cancer (NSCLC), points out the development direction for late NSCLC treatment, and also provides theoretical reference for more primary hospital doctors, as well as professional interpretation of the guidelines recommended to help improve the overall level of lung cancer treatment in China.
-
Br J Cancer: EGFR - stable marker of bone metastasis in prostate cancer.
Time of Update: 2020-10-04
EGFR over-expression in primary tumors tracked the over-expression status of EGFR in metastasis (EGFRover) in metastasis samples of 1,039 primary tumors, 39 circulating tumor cells in high-risk patients with Damico, and 21 cases of de-resistance PCa.
-
Nat Commun: Double blocking cd47 and HER2 can eliminate radiotherapy resistance in breast cancer cells.
Time of Update: 2020-10-04
CD47 and HER2 in a variety of cancers, the study found that CD47-mediated anti-devouration increased in radiotherapy-resistant breast cancer (BC) cells, while HER2 expression levels increased.
further studies have shown that in breast tumors in esophageal mice, the double antibodies of these two subject proteins have a synergetic anti-cancer effect with RT.
-
Br J Cancer: Sapanisertib treats advanced solid tumors.
Time of Update: 2020-10-04
, in the Phase 1 study, the drug Sapanisertib showed controlled safety and initially observed anti-tumor activity in renal cell carcinoma and endometrial cancer.
-
Clin Cancer Res: Apatamine is used for non-metastatic desopathic prostate cancer exposure-response analysis.
Time of Update: 2020-10-04
Objective: The purpose of this study was to evaluate the relationship between apalutamine (apalutamide) and its active metabolite N-methamphetamine exposure, as well as the application of selected clinical efficacy and safety parameters in patients with high-risk non-metastatic despotic resistance prostate cancer.
-
2020 ESMO: Infineon has a major breakthrough in the treatment of stage III non-small cell lung cancer, and about 50% of patients have a four-year survival period
Time of Update: 2020-10-04
Updated results from Phase III PACIFIC clinical trials show that AstraZeneur's Infinfan (chemical name: Durvalumab, commodity name: Infinzi) showed sustained and clinically significant total survival (OS) and disease-free progression in patients with non-removable non-small cell lung cancer (NSCLC) who did not develop the disease after receiving simultaneous radiotherapy (CRT).
-
The numbness of the lower limbs, accompanied by unstable standing, is the scourge of a huge dumbbell-like tumor.
Time of Update: 2020-10-04
Ms. Kang, 57, was numb to her lower limbs, low back pain, and then slowly developed to stand unstable, the local hospital MRI showed that there is a huge tumor inside and outside her vertebral tube, dumbbell-shaped, has grown to the chest cavity, about 8 cm long, the original finger thick spine because of pressure has become as thin as paper, so she came to the Southern Medical University Third Affiliated Hospital (here is "Southern Medical Hospital").
-
ESMO: 50% of patients with advanced NSCLC benefit from excellent survival with up to 4 years of survival degree Vale eu monoantitherapy.
Time of Update: 2020-10-04
39 Health has learned that the latest Phase III PACIFIC clinical trial update results show that AstraZeneve's Infinfan (chemical name: Dovaleyu single anti-Durvalumab, product name: Infinfan Imfinzi) in the receiving of simultaneous release In patients with non-removable non-small cell lung cancer (NSCLC) who did not show disease progression after chemotherapy (CRT), the benefits of continuous and clinically significant total survival (OS) and disease-free progression survival (PFS) were shown.
-
Lancet oncol: Phase III Trial: Overall prognostication of patients with PD-L1 inhibitor Durvalumab-Qumei single anti-treatment metastatic urethrial skin cancer.
Time of Update: 2020-10-04
In the safe population, there were 47 (14%) 3/4 treatment-related adverse reactions in 345 patients in the Durvalumab single-drug group, while 93 cases (27%) and 188 (60%) were reported in the combined and chemotherapy groups, respectively.
-
CDE Issues Technical Guidelines for Pharmaceutical Research and Evaluation of Gene Therapy Products (Draft for Comments)
Time of Update: 2020-10-04
comments, it is pointed out that the guiding principle does not include lysovirus products and CAR-T cells and other ionoid gene modification cell therapy products, but some of the relevant research of such products, such as the preparation of viral vectors, under appropriate conditions can be used for comprehensive reference.
-
The hoarseness test turned out to be throat cancer, and the doctor warned against these symptoms.
Time of Update: 2020-10-04
And for the larger one-sided T2 or T3 sound door throat cancer, some of the patients can also use the oral laser microscopic surgery, but need to remove a wider range of throat tissue, postoperative tissue defects are more, if not repaired in time, after treatment of the pronunciation effect is relatively poor, hoarse voice serious, patients talk laborily and difficult to identify speech content.
